Novo Nordisk (NVO) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Company Performance - Novo Nordisk's stock price decreased by 2.09% to $38.02, underperforming the S&P 500's daily loss of 1.52% [1] - Over the past month, shares have depreciated by 20.33%, significantly worse than the Medical sector's loss of 3.1% and the S&P 500's loss of 2.25% [1] Financial Projections - The upcoming earnings per share (EPS) for Novo Nordisk is projected at $0.86, indicating a 6.52% decrease from the same quarter last year [2] - The Zacks Consensus Estimate for revenue is $11.23 billion, reflecting a 1.99% increase from the previous year [2] - For the full year, projected earnings are $3.33 per share and revenue is $43.91 billion, representing declines of 15.91% and 6.13% respectively from the prior year [3] Analyst Estimates and Rankings - Recent changes to analyst estimates for Novo Nordisk are crucial for investors, as positive revisions can indicate a favorable business outlook [3] - The Zacks Rank system, which evaluates estimate changes, currently ranks Novo Nordisk at 4 (Sell), with the EPS estimate moving 0.36% lower over the past month [5] Valuation Metrics - Novo Nordisk's Forward P/E ratio is 11.68, which is lower than the industry average Forward P/E of 15.66 [6] - The Large Cap Pharmaceuticals industry, part of the Medical sector, has a Zacks Industry Rank of 205, placing it in the bottom 17% of over 250 industries [6]